Start with its own history
At 82.83×, LHCG is 124.6% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
82.83×
124.6% abovethe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 82.83 for every 1 of reported earnings per share.
Annual period-end data · 18 observations
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2022 | 82.08× | +173.3% |
| Dec 31, 2021 | 30.03× | -49.9% |
| Dec 31, 2020 | 59.92× | +33.5% |
| Dec 31, 2019 | 44.87× | +9.5% |
| Dec 31, 2018 | 41.00× | +89.4% |
| Dec 31, 2017 | 21.64× | -1.5% |
| Dec 31, 2016 | 21.97× | -9.8% |
| Dec 31, 2015 | 24.35× | -0.8% |
| Period end | P/E | Change |
|---|---|---|
| Dec 31, 2014 | 24.55× | +33.8% |
| Dec 31, 2013 | 18.35× | +32.7% |
| Dec 31, 2012 | 13.83× | N/M |
| Dec 31, 2011 | N/M | N/M |
| Dec 31, 2010 | 11.15× | +6.8% |
| Dec 31, 2009 | 10.44× | -51.0% |
| Dec 31, 2008 | 21.30× | -6.2% |
| Dec 31, 2007 | 22.71× | -4.4% |
| Dec 31, 2006 | 23.76× | -5.9% |
| Dec 31, 2005 | 25.26× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
LHCG This stockLHC Group, Inc. | 82.83× |
AMEDAmedisys, Inc. | 76.51× |
SYNHSyneos Health, Inc. | 16.72× |
ISEEIVERIC bio, Inc. | N/M |
NARIInari Medical, Inc. | N/M |
RCMR1 RCM Inc. | 1811.39× |
ABCMAbcam plc | 578.30× |
ASTHAstrana Health, Inc. | 26.76× |
OPTOpthea Limited | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 82.83×, LHCG is 124.6% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 5 positive peer ratios above is 76.51×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("LHCG", "PE Ratio", "LQ")Share price 169.81 ÷ EPS 2.05 = 82.83×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Not supplied; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.